Secondary causes of hypertension.
暂无分享,去创建一个
[1] T. Young,et al. Prospective study of the association between sleep-disordered breathing and hypertension. , 2000, The New England journal of medicine.
[2] V. Somers,et al. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. , 1999, Circulation.
[3] W. Young,et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. , 2003, The Journal of clinical endocrinology and metabolism.
[4] S. Textor,et al. Resistant Hypertension: Comparing Hemodynamic Management to Specialist Care , 2002, Hypertension.
[5] H. Barros. Accuracy of twenty‐four‐hour ambulatory blood pressure monitoring (night–day values) for the diagnosis of secondary hypertension , 1995, Journal of hypertension.
[6] K. Bailey,et al. Blood pressure load--a better determinant of hypertension. , 1988, Mayo Clinic proceedings.
[7] P. Torjesen,et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment , 2004, Journal of hypertension.
[8] D. Calhoun,et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. , 2007, Chest.
[9] H. Black,et al. Resistant hypertension in a tertiary care clinic. , 1991, Archives of internal medicine.
[10] T. MacDonald,et al. Is aldosterone the missing link in refractory hypertension?: aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity , 2002, Journal of Human Hypertension.
[11] F. Fuchs,et al. Obstructive sleep apnea and resistant hypertension: a case-control study. , 2007, Chest.
[12] E. Boerwinkle,et al. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. , 2001, Mayo Clinic proceedings.
[13] T. Goodfriend,et al. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. , 2004, Hypertension.
[14] K. Tsuchiya,et al. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. , 2003, The Journal of clinical endocrinology and metabolism.
[15] T. Grobner. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[16] D. Goff,et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.
[17] S. Textor. Renovascular hypertension in 2007: Where are we now? , 2007, Current cardiology reports.
[18] T. Grobner,et al. Gadolinium and nephrogenic systemic fibrosis. , 2007, Kidney international.
[19] R. D'Agostino,et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. , 2006, American heart journal.
[20] G. Eknoyan,et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.
[21] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[22] Thomas Penzel,et al. Effect of Nasal Continuous Positive Airway Pressure Treatment on Blood Pressure in Patients With Obstructive Sleep Apnea , 2003, Circulation.
[23] M. Walther,et al. Biochemical diagnosis of pheochromocytoma: which test is best? , 2002, JAMA.
[24] H. Black,et al. Resistant hypertension revisited: a comparison of two university-based cohorts. , 2005, American journal of hypertension.
[25] F. Abboud,et al. Sympathetic neural mechanisms in obstructive sleep apnea. , 1995, The Journal of clinical investigation.
[26] S. Textor,et al. Renal-artery stenosis. , 2001, The New England journal of medicine.
[27] D. Calhoun,et al. Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension , 2002, Hypertension.
[28] M. Brown,et al. Is resistant hypertension really resistant? , 2001, American journal of hypertension.
[29] W Zidek,et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. , 2000, The New England journal of medicine.
[30] D. Grobbee,et al. High Prevalence of Secondary Hypertension and Insulin Resistance in Patients with Refractory Hypertension , 2003, Blood pressure.